Last month, an average of about 350 people died each week from COVID, according to data from the CDC. With available vaccines ...

Researchers have discovered in a new study that using Paxlovid (nirmatrelvir/ritonavir) early in the course of ...

Pfizer’s first-quarter revenue missed analyst estimates as it faces an “uncertain and volatile external environment.” ...

Pfizer (NYSE: PFE) is a great example, with its shares down around 57% below the previous high. When a stock plunges as much ...

More than five years after COVID-19 first appeared in the United States, hundreds of people continue to die from the virus ...

Here is why Pfizer can't seem to get off the mat and whether it's worth buying the dip on today. Image source: . Pfizer has a ...

A new COVID-19 subvariant, NB.1.8.1, is spreading globally, with a recent surge in infections in Asia and detection in the US ...

The risk for COVID-19-related hospitalization was not significantly different between vaccinated older adults with vs without age-restrictive access to nirmatrelvir-ritonavir.

The antiviral, also known as Paxlovid, is no longer cost effective in the over-70s as well as people with diabetes, obesity and heart failure, the new recommendations said. It follows a partial review ...

The U.S. Government Patient Assistance Program (USG PAP), operated by Pfizer, will provide eligible Medicare beneficiaries with free Paxlovid access until December 31, 2025. This program is also ...

An infectious diseases specialist separates fact from fiction, powering us with information about symptoms, treatments, precautions and more ...